Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...